SL-172154 is a fusion protein commercialized by Shattuck Labs, with a leading Phase I program in Metastatic Ovarian Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 1 was completed, 2 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of SL-172154’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for SL-172154 is expected to reach an annual total of $20 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
SL-172154 Overview
SL-172154 is under development for the treatment of advanced or metastatic ovarian cancer, epithelial ovarian cancer, primary peritoneal cancer, fallopian tube cancer, acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS). The drug candidates are based on Agonist Redirected Checkpoints (ARC) technology. The drug candidate is a two-sided human fusion protein incorporating the ECDs of SIRPα and CD40L, adjoined by a central Fc domain termed as SIRPα-Fc-CD40L. It is administered through intravenous route.
It was under development for the treatment of recurrent head and neck cancer squamous cell carcinoma, cutaneous squamous cell carcinoma, skin cancer, colon cancer and hematological malignancies.
Shattuck Labs Overview
Shattuck Labs is a biotechnology company that develops novel therapeutics for the treatment of cancer and autoimmune diseases. The company’s lead product candidate is SL-172154, a compound currently in global clinical trials for the treatment of cancer. The company utilizes the ARC platform. Shattuck Labs products are primarily used in the medical field, specifically in the treatment of cancer and autoimmune diseases. Shattuck Labs is headquartered in Durham, North Carolina, US.
The company reported revenues of (US Dollars) US$1.7 million for the fiscal year ended December 2023 (FY2023), compared to a revenue of US$0.7 million in FY2022. The operating loss of the company was US$92 million in FY2023, compared to an operating loss of US$103.3 million in FY2022. The net loss of the company was US$87.3 million in FY2023, compared to a net loss of US$101.9 million in FY2022.
For a complete picture of SL-172154’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
